Compare AVX & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | HOWL |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7M | 17.9M |
| IPO Year | 2020 | 2021 |
| Metric | AVX | HOWL |
|---|---|---|
| Price | $3.65 | $0.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 19.7K | ★ 9.5M |
| Earning Date | 05-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.55 | 18.40 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,340,811.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3348.10 | N/A |
| 52 Week Low | $0.35 | $0.27 |
| 52 Week High | $6.40 | $2.23 |
| Indicator | AVX | HOWL |
|---|---|---|
| Relative Strength Index (RSI) | 58.04 | 85.95 |
| Support Level | $0.50 | $0.80 |
| Resistance Level | $3.92 | $0.90 |
| Average True Range (ATR) | 0.35 | 0.04 |
| MACD | 0.06 | 0.05 |
| Stochastic Oscillator | 72.88 | 75.21 |
AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. It is leveraging the proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. It has one reportable segment, which focuses on the discovery and development of cancer therapeutics.